Skip to content

Multiomics in systemic inflammation driven brain aging in humans

Multiomics in systemic inflammation driven brain aging in humans - UNCOVERS

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON56946
Enrollment
Unknown
Registered
2024-08-12
Start date
2024-05-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative cerebral dysfunction Postoperative cognitive decline (POCD)

Interventions

None listed

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Planned for elective thoraco-abdominal aortic aneurysm repair that also have an ELD as part of their routine clinical care at Radboudumc

Exclusion criteria

Exclusion criteria: - Disease states associated with a state of neuroinflammation: brain or spinal surgery within the last 6 months, meningitis or brain infection within the last 6 months, presence of a CSF catheter or shunt, presence of known brain tumor, brain injury (e.g., stroke, or subarachnoid hemorrhage) within the last 12 months, moderate-severe brain trauma in previous medical history, chronic active alcoholism or substance use. - Pre-existing dementia or neurodegenerative disease - Cognitive impairment interfering with the ability to understand informational study material. - Chronic (>2 weeks) use of immunosuppressive agents (see table 3.3.A, below) - Concomitant diseases resulting in severe immunosuppression (e.g., HIV, hematological malignancies) - Patients that do not speak Dutch or analphabetic patients.

Design outcomes

Primary

MeasureTime frame
Primary endpoint are biological pathways and markers based on transcriptomic and epigenetic data, with patients divided into two groups based on cognitive assessment after 6 months.

Secondary

MeasureTime frame
Primary endpoint are biological pathways and markers based on transcriptomic and epigenetic data, with patients divided into two groups based on cognitive assessment after 12 months.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)